UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era

Journal of clinical oncology, 2010-05, Vol.28 (14), p.2373-2380

2010

Link zum Volltext

Verfügbarkeit prüfen

Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging

PloS one, 2011-03, Vol.6 (3), p.e17487

2011

Link zum Volltext

Verfügbarkeit prüfen

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis

Blood, 2013-10, Vol.122 (18), p.3220-3229

2013

Link zum Volltext

Verfügbarkeit prüfen

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

The Lancet (British edition), 2012-05, Vol.379 (9828), p.1791-1799

2012

Link zum Volltext

Verfügbarkeit prüfen

How I treat elderly patients with diffuse large B-cell lymphoma

Blood, 2010-12, Vol.116 (24), p.5103-5110

Pfreundschuh, Michael

2010

Link zum Volltext

Verfügbarkeit prüfen

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

Journal of clinical oncology, 2009-02, Vol.27 (4), p.511-518

2009

Link zum Volltext

Verfügbarkeit prüfen

Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4548-4554

2009

Link zum Volltext

Verfügbarkeit prüfen

TP53 mutation and survival in aggressive B cell lymphoma

International journal of cancer, 2017-10, Vol.141 (7), p.1381-1388

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4115-4122

2013

Link zum Volltext

Verfügbarkeit prüfen

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

The lancet oncology, 2008-02, Vol.9 (2), p.105-116

2008

Link zum Volltext

Verfügbarkeit prüfen

RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1364-1372

2011

Link zum Volltext

Verfügbarkeit prüfen

New drugs for aggressive B-cell and T-cell lymphomas

The lancet oncology, 2010-11, Vol.11 (11), p.1074-1085

2010

Link zum Volltext

Verfügbarkeit prüfen

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

Blood, 2008-06, Vol.111 (12), p.5486-5495

2008

Link zum Volltext

Verfügbarkeit prüfen

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

The lancet oncology, 2014-06, Vol.15 (7), p.757-766

2014

Link zum Volltext

Verfügbarkeit prüfen

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients

British journal of haematology, 2017-11, Vol.179 (3), p.410-420

2017

Link zum Volltext

Verfügbarkeit prüfen

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group

Journal of clinical oncology, 2014-12, Vol.32 (36), p.4127-4133

2014

Link zum Volltext

Verfügbarkeit prüfen

Effects of Physical Exercise on Myocardial Telomere-Regulating Proteins, Survival Pathways, and Apoptosis

Journal of the American College of Cardiology, 2008-08, Vol.52 (6), p.470-482

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study

Arthritis research & therapy, 2009-01, Vol.11 (5), p.R140-R140

2009

Link zum Volltext

Verfügbarkeit prüfen

High-dose chemotherapy and autologous stem-cell transplantation for DLBCL in the rituximab era

The lancet oncology, 2017-08, Vol.18 (8), p.989-991

Pfreundschuh, Michael

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study

PloS one, 2017-01, Vol.12 (1), p.e0169512-e0169512

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 559

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(530)
Mit Volltextzugriff
(534)

Publikationsform

Sprache

Englisch
(551)
Japanisch
(54)
Deutsch
(10)

Erscheinungsjahr

n.n

Thema

Humans
(303)
Science & Technology
(301)
Life Sciences & Biomedicine
(285)
Male
(162)
Oncology
(161)
Female
(159)
Middle Aged
(154)
Biological And Medical Sciences
(141)
Medical Sciences
(136)
Adult
(124)
Aged
(120)
Hematology
(116)
Treatment Outcome
(68)
Hematologic And Hematopoietic Diseases
(66)
Adolescent
(65)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(61)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(61)
Tumors
(60)
Immunology
(52)
Prognosis
(50)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

How I treat elderly patients with diffuse large B-cell lymphoma

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

TP53 mutation and survival in aggressive B cell lymphoma

Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement

Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group

New drugs for aggressive B-cell and T-cell lymphomas

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group

Effects of Physical Exercise on Myocardial Telomere-Regulating Proteins, Survival Pathways, and Apoptosis

Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study

High-dose chemotherapy and autologous stem-cell transplantation for DLBCL in the rituximab era

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study

Suchergebnisse filtern